These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 2176932)

  • 21. Comparison of granisetron, ondansetron, and tropisetron in the prophylaxis of acute nausea and vomiting induced by cisplatin for the treatment of head and neck cancer: a randomized controlled trial.
    Mantovani G; Macciò A; Bianchi A; Curreli L; Ghiani M; Proto E; Santona MC
    Cancer; 1996 Mar; 77(5):941-8. PubMed ID: 8608488
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The budgetary impact of 5-HT3 receptor antagonists in the management of chemotherapy-induced emesis.
    Jones AL; Lee GJ; Bosanquet N
    Eur J Cancer; 1992; 29A(1):51-6. PubMed ID: 1332738
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Comparison of the antiemetic effectiveness of granisetron and alizapride plus dexamethasone in cytostatic therapy].
    Bremer K; Uhlenbusch R
    Dtsch Med Wochenschr; 1991 Nov; 116(48):1817-23. PubMed ID: 1659980
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Granisetron plus methylprednisolone for the control of high-dose cisplatin-induced emesis.
    Kleisbauer JP; García-Girón C; Antimi M; Azevedo MC; Balmes H; Massuti-Sureda B; Contu A; Luque A; Pellier P
    Anticancer Drugs; 1998 Jun; 9(5):387-92. PubMed ID: 9660534
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibitory effect of zacopride on Cisplatin-induced delayed emesis in ferrets.
    Yamakuni H; Nakayama H; Matsui S; Imazumi K; Matsuo M; Mutoh S
    J Pharmacol Sci; 2006 May; 101(1):99-102. PubMed ID: 16651699
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A comparative study of the use of granisetron, a selective 5-HT3 antagonist, versus a standard anti-emetic regimen of chlorpromazine plus dexamethasone in the treatment of cytostatic-induced emesis. The Granisetron Study Group.
    Marty M
    Eur J Cancer; 1990; 26 Suppl 1():S28-32. PubMed ID: 2169783
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Optimal control of acute cisplatin-induced emesis.
    Verweij J; de Wit R; de Mulder PH
    Oncology; 1996 Jun; 53 Suppl 1():56-64. PubMed ID: 8692553
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 5-HT3 receptor antagonists, a new approach in emesis: a review of ondansetron, granisetron and tropisetron.
    Seynaeve C; Verweij J; de Mulder PH
    Anticancer Drugs; 1991 Aug; 2(4):343-55. PubMed ID: 1665723
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of granisetron in the prevention of chemotherapy-induced emesis in paediatric patients.
    Lemerle J; Amaral D; Southall DP; Upward J; Murdoch RD
    Eur J Cancer; 1991; 27(9):1081-3. PubMed ID: 1659848
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Medical treatment of chemotherapy-induced nausea and vomiting].
    Herrstedt J
    Ugeskr Laeger; 2007 Feb; 169(9):799-805. PubMed ID: 17355844
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Granisetron. A review of its pharmacological properties and therapeutic use as an antiemetic.
    Plosker GL; Goa KL
    Drugs; 1991 Nov; 42(5):805-24. PubMed ID: 1723376
    [TBL] [Abstract][Full Text] [Related]  

  • 32. BRL 43694.
    Cancer Invest; 1989; 7(5):535. PubMed ID: 2559785
    [No Abstract]   [Full Text] [Related]  

  • 33. Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group.
    Navari RM; Reinhardt RR; Gralla RJ; Kris MG; Hesketh PJ; Khojasteh A; Kindler H; Grote TH; Pendergrass K; Grunberg SM; Carides AD; Gertz BJ
    N Engl J Med; 1999 Jan; 340(3):190-5. PubMed ID: 9917226
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Are all 5-HT3 receptor antagonists the same?
    Andrews PL; Bhandari P; Davey PT; Bingham S; Marr HE; Blower PR
    Eur J Cancer; 1992; 28A Suppl 1():S2-6. PubMed ID: 1320915
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 5-HT3 receptor antagonists in the control of cisplatin-induced delayed emesis.
    Ossi M; Anderson E; Freeman A
    Oncology; 1996 Jun; 53 Suppl 1():78-85. PubMed ID: 8692556
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of specific 5-HT3 receptor antagonism in the control of cytostatic drug-induced emesis.
    Blower PR
    Eur J Cancer; 1990; 26 Suppl 1():S8-11. PubMed ID: 2169786
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The serotonin type 3 receptor antagonist BRL 43694 and nausea and vomiting induced by cisplatin.
    Carmichael J; Cantwell BM; Edwards CM; Rapeport WG; Harris AL
    BMJ; 1988 Jul; 297(6641):110-1. PubMed ID: 2841996
    [No Abstract]   [Full Text] [Related]  

  • 38. [Recent improvements in antiemetic therapy].
    Roila F; Palladino MA; Ciccarese G; Basurto C
    Tumori; 1997; 83(2 Suppl):S3-14. PubMed ID: 9235727
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of granisetron, a selective 5-HT3 receptor antagonist, on ouabain-induced emesis in ferrets.
    Endo T; Sugawara J; Nemoto M; Minami M; Blower PR
    Res Commun Mol Pathol Pharmacol; 1998 Dec; 102(3):227-39. PubMed ID: 10342910
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Granisetron versus tropisetron for prophylaxis of acute chemotherapy-induced emesis: a pooled analysis.
    Jordan K; Hinke A; Grothey A; Schmoll HJ
    Support Care Cancer; 2005 Jan; 13(1):26-31. PubMed ID: 15668744
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.